Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)
Phase of Trial: Phase III
Latest Information Update: 17 Aug 2017
At a glance
- Drugs SCY 078 (Primary)
- Indications Candidiasis
- Focus Expanded access; Therapeutic Use
- Acronyms FURI
- Sponsors SCYNEXIS
- 07 Apr 2017 Status changed from not yet recruiting to recruiting.
- 13 Mar 2017 According to a Scynexis media release, expected enrollment for patients in this study to commence in the first half of 2017.
- 02 Mar 2017 New trial record